These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 8097388

  • 1. Human breast cancer: correlation study between HER-2/neu amplification and prognostic factors in an unselected population.
    Descotes F, Pavy JJ, Adessi GL.
    Anticancer Res; 1993; 13(1):119-24. PubMed ID: 8097388
    [Abstract] [Full Text] [Related]

  • 2. Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients.
    Imyanitov EN, Chernitsa OI, Serova OM, Nikoforova IF, Pluzhnikova GF, Knyazev PG.
    Neoplasma; 1993; 40(1):35-9. PubMed ID: 7688867
    [Abstract] [Full Text] [Related]

  • 3. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
    Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P.
    Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
    [Abstract] [Full Text] [Related]

  • 4. The significance of HER-2/neu/c-erbB-2 gene amplification in benign and malignant breast disease.
    Supanaranond K, Sukarayodhin S, Tanyakaset M, Balachandra K, Jullaksorn D, Rienkijkarn M, Hoisanka N, Tantivanich S.
    Southeast Asian J Trop Med Public Health; 1997 Sep; 28(3):631-40. PubMed ID: 9561622
    [Abstract] [Full Text] [Related]

  • 5. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.
    Tiwari RK, Borgen PI, Wong GY, Cordon-Cardo C, Osborne MP.
    Anticancer Res; 1992 Sep; 12(2):419-25. PubMed ID: 1349794
    [Abstract] [Full Text] [Related]

  • 6. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
    Berns EM, Klijn JG, van Putten WL, van Staveren IL, Portengen H, Foekens JA.
    Cancer Res; 1992 Mar 01; 52(5):1107-13. PubMed ID: 1737370
    [Abstract] [Full Text] [Related]

  • 7. Her-2/neu gene overexpression in breast carcinoma and its association with clinicopathological characteristics of the disease.
    Ahmad A, Bano U, Gondal M, Khan A.
    J Coll Physicians Surg Pak; 2009 May 01; 19(5):297-9. PubMed ID: 19409162
    [Abstract] [Full Text] [Related]

  • 8. HER-2/neu amplification predicts poor survival in node-positive breast cancer.
    Borg A, Tandon AK, Sigurdsson H, Clark GM, Fernö M, Fuqua SA, Killander D, McGuire WL.
    Cancer Res; 1990 Jul 15; 50(14):4332-7. PubMed ID: 1973070
    [Abstract] [Full Text] [Related]

  • 9. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    Scandinavian Breast Group Trial 9401Laboratory of Cancer Biology, Institute of Medical Technology, and Department of Oncology, Tampere University and Tampere University Hospital, Tampere, Finland., Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.
    J Clin Oncol; 2006 Jun 01; 24(16):2428-36. PubMed ID: 16682728
    [Abstract] [Full Text] [Related]

  • 10. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.
    Grushko TA, Blackwood MA, Schumm PL, Hagos FG, Adeyanju MO, Feldman MD, Sanders MO, Weber BL, Olopade OI.
    Cancer Res; 2002 Mar 01; 62(5):1481-8. PubMed ID: 11888924
    [Abstract] [Full Text] [Related]

  • 11. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
    Schmidt M, Lewark B, Kohlschmidt N, Glawatz C, Steiner E, Tanner B, Pilch H, Weikel W, Kölbl H, Lehr HA.
    Breast Cancer Res; 2005 Mar 01; 7(2):R256-66. PubMed ID: 15743506
    [Abstract] [Full Text] [Related]

  • 12. Risk of breast cancer according to the status of HER-2/neu oncogene amplification.
    Huang WY, Newman B, Millikan RC, Conway K, Hulka BS, Schell MJ, Liu ET.
    Cancer Epidemiol Biomarkers Prev; 2000 Jan 01; 9(1):65-71. PubMed ID: 10667465
    [Abstract] [Full Text] [Related]

  • 13. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
    Bhargava R, Naeem R, Marconi S, Luszcz J, Garb J, Gasparini R, Otis CN.
    Hum Pathol; 2001 Dec 01; 32(12):1344-50. PubMed ID: 11774167
    [Abstract] [Full Text] [Related]

  • 14. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
    Seshadri R, Lee CS, Hui R, McCaul K, Horsfall DJ, Sutherland RL.
    Clin Cancer Res; 1996 Jul 01; 2(7):1177-84. PubMed ID: 9816285
    [Abstract] [Full Text] [Related]

  • 15. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
    Persons DL, Borelli KA, Hsu PH.
    Mod Pathol; 1997 Jul 01; 10(7):720-7. PubMed ID: 9237184
    [Abstract] [Full Text] [Related]

  • 16. c-erbB-2 amplification in node-negative human breast cancer.
    Ro JS, el-Naggar A, Ro JY, Blick M, Frye D, Fraschini G, Fritsche H, Hortobagyi G.
    Cancer Res; 1989 Dec 15; 49(24 Pt 1):6941-4. PubMed ID: 2573424
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer.
    Homaei-Shandiz F, Ghavam-Nassiri MR, Sharifi N, Homaei-Shandiz AH, Taghizadeh-Kermani A, Torshizi SA, Ghafarzadegan K.
    Saudi Med J; 2006 Dec 15; 27(12):1810-4. PubMed ID: 17143354
    [Abstract] [Full Text] [Related]

  • 18. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
    Prati R, Apple SK, He J, Gornbein JA, Chang HR.
    Breast J; 2005 Dec 15; 11(6):433-9. PubMed ID: 16297088
    [Abstract] [Full Text] [Related]

  • 19. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
    Wang ZR, Liu W, Smith ST, Parrish RS, Young SR.
    Exp Mol Pathol; 1999 Jun 15; 66(2):140-8. PubMed ID: 10409442
    [Abstract] [Full Text] [Related]

  • 20. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
    Champème MH, Bièche I, Hacène K, Lidereau R.
    Mod Pathol; 1994 Dec 15; 7(9):900-5. PubMed ID: 7892157
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.